Company Details
- Employees
- 95
- Founded
- -
- Address
- 35 Cambridgepark Dr,
- Phone
- (+1) 617.682.6015
- in****@****lis.com
- Industry
- Biotechnology
- Website
- quralis.com
- HQ
- Cambridge, Massachusetts
Please complete the CAPTCHA to continue
QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers PR Newswire
Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome Business Wire
QurAlis Doses First Patient With ALS in Phase 1 Clinical Trial Evaluating QRL-101, a First-in-Class Kv7 Precision Therapy for ALS PR Newswire
Eli Lilly adds ALS drug prospect with QurAlis deal BioPharma Dive
QurAlis Opens New Global Headquarters Genetic Engineering and Biotechnology News
Biotech Firm QurAlis Opens New 30,000-SF Global Headquarters in Cambridge’s Alewife Biotech Park Boston Real Estate Times
Lilly gilds neuro pipeline, paying QurAlis $45M for preclinical ALS, dementia prospect Fierce Biotech
QurAlis Appoints Three New Members to Leadership Team citybiz
QurAlis' ANQUR Clinical Trial of QRL-201 in ALS Advances to Dose Range-Finding (DRF) Phase With First Participant Dosed PR Newswire
QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases PR Newswire
QurAlis Grants Lilly Exclusive Global License for QRL-204, a Potentially First-in-Class Precision Therapy That Restores UNC13A Function in ALS and FTD PR Newswire
QurAlis and Unlearn Announce Collaboration to Accelerate and Optimize ALS Clinical Trials With Generative Artificial Intelligence Technologies PR Newswire
QurAlis Strengthens Global Presence With Opening of European Headquarters That Includes R&D Manufacturing PR Newswire
QurAlis Announces Expansion of its Selective Kv7.2/7.3 Ion Channel Opener, QRL-101, Into Epilepsy PR Newswire
QurAlis Reveals Newest Program Targeting UNC13A RNA Mis-splicing Incorporating its FlexASO™ Platform PR Newswire
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia PR Newswire
QurAlis Announces First Patient Dosed With QRL-201, a First-in-Class STATHMIN-2 Precision Therapy for ALS PR Newswire
QurAlis Expands Leadership Team With Doug Williamson, M.D., as Chief Medical Officer and Jason Brown, MBA, as Chief Financial Officer and Appoints Shafique Virani, M.D., to Board of Directors PR Newswire
QurAlis' FlexASOs Show High Potency and Improved Safety Over Standard ASOs PR Newswire
QurAlis Announces the Appointment of Anne C. Whitaker as Chair of the Board PR Newswire
ALS-focused QurAlis raises $5.5M in seed money, wins Pfizer ticket to LabCentral Fierce Biotech
QurAlis Spins out Med Device Company EnClear to Target ALS BioSpace
Amgen backs Harvard professors’ ALS startup QurAlis Fierce Biotech
3 +191974XXXXX
1 +161749XXXXX
Find emails, phones & company data instantly
Your AI prospecting assistant
0 records × $0.02 per record
Secure checkout
Total price
$0.50
Enter your payment details below to complete the download. We'll email you the CSV as soon as it's ready.
Processing your payment...
Please wait while we complete your transaction
Sign in required
Create a free account or sign in to continue downloading the full results.
Sign up for a free account. No credit card required. Up to 10 free credits.
Get contact details of over 750M+ profiles across 60M companies – all with industry-leading accuracy. Sales Navigator and Recruiter users, try out our Email Finder Extension.
Find business and personal emails and mobile phone numbers with exclusive coverage across niche job titles, industries, and more for unparalleled targeting. Also available via our Contact Data API.